Mark S. Soloway

About

Dr. Mark S. Soloway is a leading urologic oncologist whose research has fundamentally shaped the management of bladder and prostate cancers. His seminal work on muscle-invasive urothelial carcinoma of the bladder (164 citations) established critical frameworks for treatment, while his pioneering cost-comparison studies on active surveillance versus radical prostatectomy for low-risk prostate cancer (63 and 11 citations) provided compelling evidence for less aggressive management strategies. Dr. Soloway's investigations into thromboembolism prophylaxis and surgical margin assessment have further refined perioperative care. Through these contributions, he has advanced the paradigm toward personalized, risk-adapted treatment, reducing overtreatment and its associated morbidity. His research, cited extensively by peers, continues to influence clinical guidelines and patient counseling, cementing his legacy as a transformative figure in urologic oncology.

Research Focus

Key Achievements

Top Papers

1. 1
   Muscle-Invasive Urothelial Carcinoma of the Bladder

   164 citations · 2007
2. 2
   Active surveillance vs. treatment for low-risk prostate cancer: A cost comparison

   63 citations · 2011
3. 3
   Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy

   11 citations · 2010
4. 4
   Thromboembolism Prophylaxis and Total Prostatectomy: Is Pharmacologic Therapy Required?

   5 citations · 2007
5. 5
   Frozen Sections for Positive Margins?

   5 citations · 2006
6. 6
   Editorial Comment on: Robotic-Assisted Laparoscopic Radical Cystectomy with Extracorporeal Urinary Diversion: Initial Experience

   4 citations · 2008

Key Collaborators

Contact & Links